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Objective: The aim of this study was to test the effectiveness of the OPTIFAST program (OP), a total meal 
replacement dietary intervention, compared with a food-based (FB) dietary plan for weight loss.
Methods: Participants with BMI 30 to 55 kg/m2, age 18 to 70 years old, were randomized to OP or FB die-
tary and lifestyle interventions for 26 weeks, followed by a weight-maintenance phase. Outcomes were 
percent change in body weight (%WL) from baseline to weeks 26 and 52, associated changes in body com-
position (using dual energy x-ray absorptiometry), and adverse events. Primary analysis used repeated-
measures multivariable linear mixed models to compare outcomes between groups in a modified 
intention-to-treat fashion (mITT).
Results: A total of 273 participants (83% of randomized; 135 OP, 138 FB) made up the mITT population. 
Mean age was 47.1 ± 11.2 years; 82% were female and 71% non-Hispanic white. Baseline BMI was 38.8 ± 5.9 
kg/m2. At 26 weeks, OP %WL was 12.4% ± 0.6% versus 6.0% ± 0.6% in FB (P < 0.001). At 52 weeks, OP 
%WL was 10.5% ± 0.6% versus 5.5% ± 0.6% in FB (P < 0.001). Fat mass loss was greater for OP; lean mass 
loss was proportional to total weight loss. There was no difference in serious adverse event rates between 
groups.
Conclusions: Compared with an FB approach, OP was more effective with greater sustained weight loss.
Obesity (2019) 27, 22-29. doi:10.1002/oby.22303
Introduction
Weight loss requires an energy deficit, usually achieved by reducing 
the volume of food consumed through modifying portions, reducing 
certain macronutrients (e.g., lower fat or lower carbohydrate intake), or 
eliminating various food groups. However, irrespective of the strategy 
employed to modify intake, weight loss at 6 to 12 months with food-
based (FB) diets averages 4% to 8% of initial body weight (1-3).
Meal replacements (MR), typically formulated as prepackaged shakes 
or bars, are another option for reducing energy intake (4,5). They help 
promote weight loss by eliminating choices, controlling portions, and 
providing satiation at lower calorie intakes (6,7). Total meal replace-
ment (TMR), or the use of MR as the sole source of daily nutrition, has 
been studied as one option to enhance behavioral weight loss.  Several 
retrospective and prospective clinical trials through the 1990s showed 
significant initial weight loss with the use of very-low-calorie diets 
(VLCD), typically providing 400 to 600 kcal/d using TMR. However, 
the 1998 expert obesity panel convened by the National Heart, Lung, 
and Blood Institute did not recommend the use of VLCDs because of 
concerns that long-term weight losses, especially after cessation of the 
VLCD, were not significantly different from those achieved with stan-
dard low-calorie diets (8). At the time of the systematic review for the 
2013 American Heart Association/American College of Cardiology/
TOS Obesity Guidelines, there was insufficient high-quality evidence 
to support more than a limited recommendation for use of these types 
of dietary strategies (3). While studies reviewed for the 2013 guidelines 
suggested that short-term TMR weight loss could be larger than that 
achieved with FB diets, the potential for weight regain after TMR still 
appeared high (3). The studies of TMR reviewed in the 2013 guide-
lines, dating from 1998 to 2009, were generally short-term studies, 
often without follow-up intervention beyond 3 to 6 months of initiation 
of TMR (3).
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The OPTIFAST program (OP) is one example of a TMR weight-loss 
intervention. Originally developed in the 1970s as a VLCD providing 
420 kcal/d, the program has evolved to include comprehensive behav-
ioral intervention and a higher calorie intake. This trial was designed to 
test the effectiveness of OP. The goal was to determine whether OP was 
more effective than an FB dietary plan and comprehensive behavioral 
intervention for weight loss at 26 and 52 weeks. We hypothesized that 
OP would lead to greater weight loss at 26 and 52 weeks and a greater 
proportion of patients achieving 5% and 10% weight loss compared 
with FB. In this report, we present the main results of the effectiveness 
of the Optifast program compared with a reduced-energy food based 
diet plan on body weight (OPTIWIN) trial, including weight-change 
outcomes, changes in body composition, and adverse events (AEs).
Methods
Setting and population
OPTIWIN was an open-label, multicenter, randomized controlled 
clinical trial. The nine participating US centers included five private 
clinics and four academic medical centers. Participants had to be 18 
to 70 years old and nonsmokers with BMI of 30 to 55 kg/m2. Key ex-
clusions included recent weight loss or use of weight-loss medications, 
previous bariatric surgery, organ failure, type 1 diabetes or hemoglo-
bin A1c > 10%, cardiovascular disease event or mental health hospi-
talization in the past 6 months, alcohol or drug dependence, positive 
screening for potential eating disorder, or poorly controlled depression. 
Volunteers were screened by telephone to assess initial eligibility, fol-
lowed by an in-person visit to confirm eligibility and obtain written in-
formed consent. Eligible individuals completed a 7-day run-in diet that 
included use of one serving of MR (OPTIFAST; Nestlé Health Science, 
Bridgewater, New Jersey) daily to assess tolerance to the product. The 
final screening visit was completed after the run-in to assess adher-
ence to the run-in diet, self-monitoring tasks, and final eligibility. This 
study was overseen and approved by a central institutional review 
board (Quorum) after review by each site’s institutional review board 
and was registered on ClinicalTrials.gov (NCT02635698).
Treatment arms
OP. Participants randomized to OP were provided all MR at no cost. 
Participants with BMI < 45 were instructed to use five MRs per day 
(800 kcal total) with 40% of calories as protein, 40% as carbohydrate, 
and 20% as fat. Participants with BMI of 45 to 49.9 received six MRs 
per day (960 kcal); those with BMI ≥ 50 received six MRs plus one 
meal daily of lean protein (3-4 ounces) and one nonstarchy vegetable 
serving (1,100-1,200 kcal). Participants followed their prescription for 
12 to 16 weeks based on provider discretion and patient preference, 
after which there was gradual reintroduction of food through week 
26. After week 26, participants’ calories were gradually increased to 
achieve weight stability. During this time, participants were advised to 
use one to two MRs daily to facilitate weight-loss maintenance.
The OPTIFAST protocol requires medical monitoring during the ini-
tiation of TMR. OP participants saw a clinician regularly to address 
health concerns and adjust medications for a total of 11 medical mon-
itoring visits during the first 26 weeks and 4 medical monitoring vis-
its in weeks 27 to 52. Labs for medical monitoring, including either a 
basic or comprehensive metabolic panel, were obtained at weeks 2, 4, 
6, 8, 10, 12, and 16. Participants had individual counseling with trained 
interventionists for a total of 16 individual counseling visits through 
the first 26 weeks and 11 individual counseling visits from week 27 
through week 52.
FB program. The FB program was a modified version of the Diabetes 
Prevention Program (DPP) intervention (9-11). During active weight 
loss (0-26 weeks), FB participants were prescribed a calorie-restricted 
diet emphasizing lower fat intake (25%-30% of total calories). They 
were advised to reduce calories by 500 to 750 kcal below estimated 
total energy expenditure, calculated based on resting metabolic rate 
measured by indirect calorimetry (MedGem; Microlife USA, Inc., 
Clearwater, Florida) plus an activity factor based on self-reported 
physical activity. To balance the incentive of free MR in the OP 
arm, FB participants received gift cards totaling $800 to offset the 
cost of groceries during the active weight-loss phase. They also had 
two medical monitoring visits and seven individual counseling visits 
through week 26. During the maintenance phase (27-52 weeks), they 
had two medical monitoring visits and five individual counseling visits.
Comprehensive behavioral program. Both treatment groups had 
weekly 45- to 60-minute group behavioral sessions for the duration 
of the intervention. Group sessions were facilitated by trained 
professional interventionists using a standardized intervention manual. 
OP program sessions used the OPTIFAST Lifestyle Education Series 
content as the basis for the behavioral group sessions. The FB program 
used the DPP’s Group Lifestyle Balance program (9).
Both groups received prescriptions for physical activity that included a 
graduated target of 150 to 180 min/wk of moderate to vigorous exercise. 
Participants were instructed to record daily food and beverage intake 
and minutes of exercise using written journals, which were reviewed 
weekly by the interventionist.
Study measures
Body weight was measured in light clothing on digital scales to the 
nearest 0.1 lb. Height was measured without shoes using a wall-mounted 
stadiometer to the nearest 0.5 cm. BMI was calculated as weight in 
kilograms divided by height in meters squared. Waist circumference 
was measured using a spring-loaded tape measure (Gulick) 1 cm above 
the umbilicus. Two measures were averaged at each study visit. Body 
composition was measured using dual-energy x-ray absorptiometry. 
Physical activity was measured using a triaxial accelerometer (Philips 
Actiware, CT, Andover, Massachusetts) worn on the wrist for 7 days.
AEs were ascertained at each clinic encounter or study visit using a 
standardized symptom checklist and questionnaire. Any new symptoms 
or medical problems were logged as AEs. The site medical provider 
reviewed each event and adjudicated the severity, relatedness, and clas-
sification. Because the FB group had fewer contacts with study person-
nel, the number of opportunities for reporting AEs was higher for the 
OP group. To adjust the AE frequency for the number of contacts, rates 
of AEs were also reported as the number of events per contact.
Analysis
Sample size was calculated primarily to show effectiveness of OP 
compared with FB on percent weight change at 52 weeks. To obtain 
90% statistical power based on a two-sided test assuming α = 0.05, 113 
participants per study group were required to detect a mean difference 
in weight change of 5% with an estimated standard deviation (SD) of 
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11.5%. With an estimated dropout rate of 30%, we planned to recruit 
300 participants to provide 150 participants per study group.
The coprimary outcomes were percent change in body weight from 
baseline to weeks 26 and 52, tested using a hierarchical procedure. 
First, we planned to test the week 26 outcome. If this analysis was sta-
tistically significant (P < 0.05), then the week 52 end point would be 
tested at the α = 0.05 level of significance. However, if the week 26 anal-
ysis was not statistically significant, then the week 52 analysis would be 
exploratory rather than confirmatory.
The primary analysis population was a modified intention-to-treat 
(mITT) population, consisting of randomized subjects known to have 
started the study program and have at least one postbaseline assess-
ment of body weight. For the primary analysis, we used a repeat-
ed-measures model with both random and fixed effects to compare 
the percent weight change between the OP and FB groups. The lin-
ear mixed model included a random intercept for subject, fixed visit 
effect, fixed treatment effect, and fixed baseline body weight effect, as 
well as a treatment-by-visit interaction term. The model also included 
age, race, sex, site, diabetes status, and gender as covariates. The 
final model was fit using the SAS PROC MIXED procedure using 
the RANDOM and LSMEANS statements (SAS Institute, Inc., Cary, 
North Carolina). A sensitivity analysis employed multiple imputation 
(MI) for missing body weight values at scheduled postbaseline vis-
its (weeks 12, 26, 40, and 52) in the mITT population. Imputation 
was performed separately (imputations = 50) for each treatment group 
using the SAS PROC MI procedure. Primary outcomes were then cal-
culated from the imputed data sets. For secondary outcomes including 
body composition and AE frequency, continuous measures were com-
pared using standard t tests, while categorical measures were com-
pared using χ2 tests.
Results
Study population
We screened 463 participants and confirmed eligibility on 330 participants 
(164 randomized to OP and 166 randomized to FB). There were 57 partic-
ipants who either declined further participation in the study after learning 
their randomization assignment (9 OP; 16 FB) or discontinued participa-
tion without a follow-up weight (20 OP; 12 FB); these participants were de-
mographically similar to the mITT population, except they were younger 
(42.5 years; P = 0.006) and reported less weight loss on average with prior 
attempts (0.1 kg; P < 0.001). The remaining 273 participants (135 OP; 138 
FB) made up the mITT study population (82.7% of randomized partici-
pants; Figure 1). In the mITT study population, there were 19 participants 
in the OP group (14.1%) and 25 (18.1%) in the FB group who discontinued 
participation. Participants were typically middle-aged (47.1 ± 11.2 years), 
predominately female (82%), and white (71%) (Table 1). Fifty-two percent 
had prediabetes or diabetes, 33% were being treated for hypertension, and 
Figure 1 CONSORT diagram.
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21% were being treated for dyslipidemia. OP and FB participants attended 
53.5% and 46.2% of weekly group behavioral sessions, respectively.
Weight-loss outcomes
Both treatment groups lost weight at 26 and 52 weeks (Figure 2). Percent 
weight loss at 26 weeks was 12.4% ± 0.6% for OP compared with 
6.0% ± 0.6% for FB (difference 6.4% ± 0.9%; P < 0.001). At 52 weeks, 
percent weight loss was 10.5% ± 0.6% for OP versus 5.5% ± 0.6% for 
FB (difference 4.9% ± 0.9%; P < 0.001) (Figure 2). Sensitivity analyses 
showed similar estimates for percent weight loss. Using MI to handle 
missing data showed a weight loss of 12.1% ± 0.6% and 10.1% ± 0.7% 
for OP at 26 and 52 weeks, respectively. Comparatively, FB had 
weight loss of 6.0% ± 0.6% and 5.5% ± 0.7% at 26 and 52 weeks. All 
differences between OP and FB remained significant at P < 0.001.
At week 52, higher proportions of OP participants achieved 5% (63.7%) 
and 10% weight loss (43.7%) compared with FB (42% and 21.7%, 
respectively; P < 0.001) (Figure 3). The percentage of people who lost 
15% or more of their initial weight was more than double in OP than FB 
(30% vs. 12%; P < 0.001). We also examined the proportion of partici-
pants who were nonresponders to assigned treatments, defined by a fail-
ure to lose ≥ 3% of their initial body weight. At week 26, 15.6% of OP 
and 39.1% of FB participants were nonresponders. By week 52, 23.7% 
of OP participants were nonresponders versus 43.5% of FB participants.
Changes in body composition
Changes in body composition outcomes are shown in Table 2. Changes 
in waist circumference paralleled weight loss in both treatment groups; 
however, there were greater reductions for the OP group compared with 
FB at both 26 and 52 weeks. Changes in body composition measured by 
dual-energy x-ray absorptiometry followed a similar pattern. By week 
52, mean total fat mass was decreased by 9.7 ± 10.4 kg for OP partic-
ipants. The mean reduction in total fat mass for FB participants was 
3.5 ± 6.6 kg at 52 weeks. Both treatment groups also had decreases in 
lean mass. The absolute difference was statistically significant; how-
ever, the proportion of weight loss from lean mass at 52 weeks was 
similar (23% for OP; 25.5% for FB). There was no difference in change 
in total bone mineral density by treatment group.
TABLE 1 Summary of demographic and baseline characteristics according to treatment groups
OPTIFAST program
(n  =  135)
FB program
(n  =  138)
Total
(N  =  273) P value
Age, y mean (SD) 47.1 (11.2) 47.2 (11.3) 47.1 (11.2) 0.88
Sex, n (%)
   Male 19 (14.1) 29 (21.0) 48 (18) 0.13
   Female 116 (85.9) 109 (79.0) 225 (82)
Race, n (%)
   Caucasian 100 (74.1) 95 (68.8) 195 (71) 0.10
   African American 22 (16.3) 37 (26.8) 59 (22)
   Asian/Pacific Islander 4 (3.0) 2 (1.4) 6 (2)
   Hispanic 5 (3.7) 4 (2.9) 9 (3)
   Other 4 (3.0) 0 (0) 4 (1)
Baseline characteristics
   Weight, kg, mean (SD) 106.8 (20.8) 109.9 (23.2) 108.4 (22.1) 0.26
   BMI, kg/m2, mean (SD) 38.4 (5.5) 39.2 (6.2) 38.8 (5.9) 0.26
BMI categorization, n (%)
   Overweight (25-29.9 kg/m2) 0 (0) 3 (2.2) 3 (1) 0.13
   Obesity class I (30.0-34.9 kg/m2) 44 (32.6) 38 (27.5) 82 (30)
   Obesity class II (35-39.9 kg/m2) 43 (31.9) 36 (26.1) 79 (29)
   Obesity class III (≥40 kg/m2) 48 (35.6) 61 (44.2) 109 (40)
Type 2 diabetes diagnosis, n (%) 13 (9.6) 20 (14.5) 33 (12.1) 0.22
Prediabetes diagnosis, n (%) 57 (42.2) 49 (35.5) 106 (38.8) 0.26
Number of previous weight-loss attempts,  
kg, mean (SD)
5.5 (8.3) 7.0 (9.2) 6.3 (8.8) 0.19
Typical weight loss with previous weight-loss attempts, 
kg, mean (SD)
2.1 (5.3) 2.4 (6.6) 2.2 (6.0) 0.67
Used diabetes medicationsa 14 (10%) 19 (14%) 33 (12%) 0.39
Used hypertension medicationsa 46 (34%) 43 (31%) 89 (33%) 0.61
Used lipid-modifying medicationsa 29 (21%) 29 (21%) 58 (21%) 0.92
Continuous variables compared using standard t test. Categorical variables compared using χ2 test with the exception of race, which used Fisher exact test because of small 
cell counts.
aMedication use includes use prior to study with continuation during study or medication use that started during study and either continued throughout study or ended before 
study completion.
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AEs
Mild or moderate AEs were reported by 76.8% of OP and 62.7% of FB 
participants (Table 3). Serious AEs were reported by 4.5% (7/155) of 
OP and 3.3% (5/150) of FB participants. Serious AEs in OP included 
knee pain, seventh cranial nerve paralysis, cholelithiasis, a third-de-
gree burn, abdominal pain, pyelonephritis associated with acute liver 
failure, and pancreatitis associated with cholelithiasis. In FB, serious 
AEs included postconcussion syndrome following a motor vehicle 
accident, pneumonia, vascular surgery to repair a ruptured arterial 
vessel with subsequent death, depression with suicidal ideation, and 
a wound abscess. Discontinuation rates were not statistically different 
between groups (29.3% OP; 31.9% FB; P = 0.60). Main reasons for dis-
continuation were subject request to no longer participate in the pro-
gram (11.0% OP; 18.7% FB) or lost to follow-up (11.0% OP; 9.6% FB). 
There was a total of 695 AEs reported by OP participants and 356 AEs 
reported by FB participants. When adjusted for the number of contacts 
at which participants reported symptoms or other potential AEs, the 
number of AEs per contact was 0.17 for OP and 0.24 for FB (P = 0.014).
Discussion
This clinical trial compared two behavioral weight-loss strategies, OP 
versus a modified version of DPP. Participants in the OP treatment 
arm lost 10.5% of their initial weight by 52 weeks, representing a near 
doubling of the effect on body weight seen with FB. A larger propor-
tion of participants lost 5%, 10%, or 15% of their body weight with OP, 
and a greater percentage of people responded with at least 3% weight 
loss to OP. The OP participants had greater losses of fat mass, and OP 
was well tolerated and safe. Overall, OP proved to be a more effective 
treatment than FB.
Previous trials of interventions using TMR, typically in the form 
of VLCD, suggested that short-term weight loss was much greater 
than no treatment controls or low-calorie diets. However, once the 
TMR was discontinued, weight regain led to only modest differ-
ences between the treatment arms with longer follow-up (3,12). 
In a meta-analysis of six randomized trials comparing VLCD with 
low-calorie diets with at least 1 year of follow-up, weight loss was 
6.4% ± 2.7% greater for VLCD used on average for 12.7 weeks. 
However, longer-term weight loss (mean follow-up 1.9 ± 1.6 years) 
was not significantly different between the groups (VLCD 1.3% 
greater weight loss; P > 0.2) (12). The 2013 AHA/ACC/TOS Obesity 
Guidelines included four VLCD trials that met the inclusion criteria 
for the systematic review. Weight losses from 14 to 17 weeks ranged 
from 14.2 to 21.1 kg; during observational follow-up, weight regain 
was 3.1 to 3.7 kg through 38 weeks. In two of the trials that tested 
interventions for weight-loss maintenance, weight regain was 5.9 to 
9.7 kg through 33 months (3).
In OPTIWIN, OP achieved greater weight loss through 12 months, 
experiencing less of the weight regain previously seen in TMR inter-
ventions. One difference from prior trials that may account for sus-
tained weight loss after TMR in our study is the presence of an active 
strategy for weight-loss maintenance, including continued behav-
ioral therapy coupled with recommendations to use one to two MRs 
per day. Continuation of behavioral treatment is recognized as a crit-
ical component for improving maintenance of weight loss; however, 
ongoing modification of calorie intake to achieve energy balance in a 
weight-reduced state continues to be a major challenge for weight-loss 
maintenance. Following TMR with ongoing use of MR for weight-loss 
maintenance may be advantageous because of the characteristics of MR 
associated with lower energy intake (e.g., portion control, low calories, 
reduced choice) and because of changes in an individual’s subjective 
cravings and desire for food, which have been objectively supported 
by functional magnetic resonance imaging showing contemporaneous 
changes in the brain regions responsible for regulation of food intake 
and reward (6).
Two prior studies lend some support to the idea that continued treat-
ment and use of MR can be important for ongoing maintenance of 
lost weight. Vazquez et al. showed in a randomized trial of adults 
who lost at least 5% of their weight in 6 months using diet alone that 
use of one MR as a substitute for dinner was effective for maintaining 
Figure 2 Relative weight change by treatment group at 26 weeks and 52 weeks. 
Percent weight change values are calculated from a least square means from a 
linear mixed model. The linear mixed model contains a random intercept subject 
effect, fixed visit effect, fixed treatment effect, fixed baseline body weight effect, 
treatment-by-visit interaction term, and covariates including age, race, sex, site, 
and reported baseline diabetes status.
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weight loss over the next 6 months (83.9% of participants) compared 
with diet alone (58.1%) (13). The importance of continuing active 
treatment can be highlighted by comparing results from a study by 
Argas et al. in which OPTIFAST was used to induce weight loss, 
and those who achieved 5% weight loss were randomized to one of 
four maintenance strategies involving use of regular or prepackaged 
foods. After 12 weeks of TMR, participants achieved approximately 
15 kg of weight loss (14). Behavioral intervention continued for 9 
months after the TMR phase, and weight loss for all treatment groups 
was 12.1 to 15 kg, suggesting continued maintenance of weight loss. 
However, after discontinuation of the behavioral treatment, signifi-
cant weight regain was noted at 18 months post randomization in all 
groups (14).
Nutritional differences in OPTIWIN may have affected weight-loss 
maintenance as well. The OP caloric prescription has increased 
over time. Previously, all patients would be initiated on 420 kcal/d. 
Currently, the lowest recommended calorie prescription is 800 kcal/d 
with allowances for additional calories for higher initial body weight. 
The OP diet also provided a higher percentage of calories from pro-
tein compared with the FB diet. The higher percentage of calories 
from protein may have contributed to the observed maintenance 
of weight loss, as higher protein intakes have been associated with 
greater satiation, leading to better weight-loss maintenance (15). 
Additional research is needed to quantify how much these dietary fac-
tors influence weight-loss maintenance and the durability of weight-
loss differences beyond 12 months, as this is relatively early in the 
weight-maintenance process.
This is the largest randomized controlled trial of TMR in the United 
States, which allowed us to recruit a broad population of individu-
als with obesity. The length of intervention and generalizable study 
population help to address the acceptability of TMR as part of a 
behavioral weight-loss strategy. In our study population, attrition was 
approximately 25% (229/305 participants who started intervention). 
However, the discontinuation rate was similar for OP and FB, sug-
gesting a TMR strategy is an acceptable strategy for those actively 
seeking to lose weight. The rate of AEs was slightly lower for the 
OP group, indicating that the increased weight loss from TMR may 
not result in more safety concerns. A suitable contemporary compar-
ison to OPTIWIN is The Diabetes Remission Clinical Trial from the 
United Kingdom (16). In this 12-month intervention, individuals with 
type 2 diabetes and BMI 27 to 45 were assigned to TMR (n = 149) or 
standard of care (n = 149) to assess impact on diabetes remission. At 1 
year, the intervention group had a mean weight change of −10.0 ± 8.0 
kg and a net of control weight loss of 8.8 kg (95% CI: 10.3-7.3). The 
Diabetes Remission Clinical Trial had a similar rate of discontinu-
ations from active treatment (21%) and serious AEs (4% of partici-
pants) as OPTIWIN (16).
The clinical impact on weight of the OP intervention relative to FB 
requires some consideration of cost-effectiveness. As a result of ana-
lyzing interventions like DPP, we know that high-intensity lifestyle 
interventions to promote weight loss can be cost effective. In years 1 
to 3, the DPP lifestyle intervention was associated with the most direct 
medical care cost per participant ($2,780) compared with metformin 
($2,542) and placebo ($79) (17). However, prevention of new onset 
diabetes in individuals with impaired glucose tolerance led to gains in 
quality-adjusted life years at a significantly lower cost than with the 
use of metformin or placebo (18). The near doubling of effect on body 
weight for OP was achieved at a higher overall cost than FB because of 
the additional medical monitoring and individual counseling. While we 
did not directly study cost effectiveness in this analysis, we are aware 
of other research that has suggested the potential for this type of inter-
vention to be cost effective. Rothberg et al. reported clinical outcomes 
and per-member per-month (PMPM) costs for University of Michigan 
TABLE 2 Change in body composition outcomes from baseline
Outcome
OPTIFAST program
(n  =  135)
FB program
(n  =  138)
P valueMean (SD)
Waist circumference (cm)
Baseline 116.6 (14.0) 119.5 (15.2) 0.10
Change at 26 weeks −12.0 (16.0) −7.7 (8.3) 0.011
Change at 52 weeks −11.9 (12.1) −7.2 (9.3) 0.0011
Total body fat mass (kg)
Baseline 49.8 (11.8) 49.7 (11.7) 0.96
Change at 26 weeks −11.3 (7.5) −4.4 (5.9) <0.0001
Change at 52 weeks −9.7 (10.4) −3.5 (6.6) <0.0001
Total body lean mass (kg)
Baseline 51.6 (9.6) 53.5 (12.1) 0.15
Change at 26 weeks −2.3 (2.8) −1.1 (3.3) 0.008
Change at 52 weeks −2.9 (5.8) −1.2 (5.9) 0.043
Bone mineral density, total (g/cm2)
Baseline 1.2 (0.1) 1.3 (0.1) 0.026
Change at 26 weeks −0.01 (0.04) −0.006 (0.03) 0.28
Change at 52 weeks −0.01 (0.04) −0.01 (0.03) 0.95
Change from baseline defined as postbaseline value − baseline value. Differences compared using standard t test.
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(UM) Weight Management Program participants (n = 153) compared 
with other insurance-covered lifestyle interventions or no treatment 
(19). The UM program utilized a treatment protocol similar to OP, 
including TMR as part of the initial dietary intervention. On average, 
participants in the UM program decreased their BMI from 40.4 ± 5.3 
to 36.2 ± 6.1 in 12 months of follow-up. The UM program was associ-
ated with an adjusted per-member per-month cost increase of only 4% 
compared with a 10% increase for Weight Watchers, 16% for a walking 
program, and 29% for those not participating in any program. The cost 
per unit BMI reduction was $146 to $148 less for the TMR program 
compared with Weight Watchers and the walking programs. Similarly, 
a recent study using event-driven decision analysis models suggested 
that OP over a 3-year period would be cost-saving compared with lira-
glutide or naltrexone/bupropion in individuals with class I to II obesity 
(20). Ultimately, additional research is needed to understand the health 
economic impact in the OPTIWIN trial. 
The results of this trial should be interpreted within the context of the 
limitations of the study design. This study was designed as a test of OP, 
not just the use of a MR; as such, conclusions about effectiveness are 
limited to the program, which included a comprehensive high-inten-
sity behavioral intervention with a weight-maintenance strategy. Future 
studies could isolate the effect of MR by matching calorie prescriptions 
between TMR and an FB diet.
The frequency of individual clinical visits was higher for OP, and this 
could bias results in favor of OP. The high frequency of contact is a fea-
ture of OP, and because the contact protocols were not equal between 
groups, we cannot make specific inferences about the individual effect 
of the TMR diet on the observed outcomes. The higher frequency of 
contact also led to ascertainment bias for AEs, potentially increas-
ing the frequency of AEs reported for the OP group. Alternatively, in 
some cases, more frequent visits may have actually prevented potential 
AEs in the OP group, whereas the FB group had more time to develop 
AEs between visits. When adjusted for the frequency of contact, we 
observed a lower rate of AEs for the OP group. However, it is possible 
that the absolute rate of AEs would be higher in the OP group even if 
ascertainment had been equal between groups.
Lastly, even though the FB group received a stipend to defray the cost 
of food, it may not have completely matched the perceived value of the 
MR as done in OP. This could have affected engagement in favor of OP.
Conclusion
This multicenter clinical trial using OP demonstrated that a compre-
hensive behavioral weight-loss intervention with TMR led to greater 
clinically significant weight loss at 26 and 52 weeks compared with a 
well-established FB behavioral intervention. It also showed the feasi-
bility of such an intervention for motivated individuals.O
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